Rapport Therapeutics, Inc. Common Stock
RAPP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | -0.47 | -0.42 | 0.00 |
| FCF Yield | -1.83% | -0.77% | -0.08% |
| EV / EBITDA | -46.78 | -106.52 | -402.20 |
| Quality | |||
| ROIC | -27.06% | -24.57% | -34.63% |
| Gross Margin | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.83 | 0.78 | 0.30 |
| Growth | |||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -133.31% | -717.27% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | 0.71 | 1.96 | 2.00 |
| Interest Coverage | 0.00 | 0.00 | -36.38 |
| Efficiency | |||
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -850.07 | -8,153.84 | -35,283.33 |